Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome
NCT ID: NCT03695822
Last Updated: 2019-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2018-12-24
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker
NCT04693897
Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin
NCT04023253
Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03044912
Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing
NCT03251300
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
NCT03059134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mirabegron
OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment
Mirabegron 25mg
The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mirabegron 25mg
The aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* \>20 years
Exclusion Criteria
20 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Far Eastern Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheng-Mou Hsiao
Chief, Department of Obstetrics & Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
107009-F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.